Joint Formulary & PAD

Guideline Profile : Oncology

Documentation

  • No records returned.

Drugs

Below are listed all drugs that are used to treat Oncology.

  • No records returned.

Committee Recommendations (1)

Cancer Drugs ( Oncology and Haematology) are to be prescribed as per Royal Surrey SACT Protocols and Policies: SACT Protocols and Policies | Royal Surrey NHS Foundation Trust. Each trust will use these drugs in accordance with locally agreed commissioned services.

Primary care will not be expected to prescribe treatments for cancer (except for specific drugs and indications that have been awarded a Blue traffic light status on the formulary e.g. LHRH analogues in breast/prostate cancer). All queries should be referred back to the appropriate trust.

Guideline Profile

Indication :
Oncology
Keywords :
St Luke’s Cancer Alliance, SACT protocols, cancer therapies, cancer treatments, cancer drugs, oncology protocols, malignancy, malignant disease, Abemaciclib, Abiraterone, Acalabrutinib, Afatinib, Alectinib, Alemtuzumab, Alpelisib, Apalutamide, Arsenic, Asciminib, Atezolizumab, Avapritinib, Avelumab, Axitinib, Azacitidine, Belzutifan, Bendamustine, Bevacizumab, Binimetinib, Bleomycin, Bortezomib, Bosutinib, Brentuximab Vedotin, Brigatinib, Busulfan, Cabazitaxel, Cabozantinib, Calcium Folinate, Capecitabine, Capivasertib, Carboplatin, Carfilzomib, Cemiplimab, Ceritinib, Cetuximab, Chlorambucil, Cisplatin, Cladribine, Crizotinib, Cyclophosphamide, Cytarabine, Dabrafenib, Dacarbazine, Daratumumab, Darolutamide, Dasatinib, Daunorubicin, Liposomal Daunorubicin With Cytarabine, Dexrazoxane, Docetaxel, Dostarlimab, Doxorubicin Hydrochloride, Doxorubicin Hydrochloride (Liposomal), Durvalumab, Elacestrant, Elranatamab, Encorafenib, Enfortumab Vedotin, Entrectinib, Enzalutamide, Epirubicin Hydrochloride, Epcoritamab, Eribulin, Erlotinib, Etoposide, Everolimus, Fedratinib, Fludarabine Phosphate, Fluorouracil (Antimetabolites), Fruquintinib, Fulvestrant, Gefitinib, Gemcitabine, Gemtuzumab Ozogamicin, Gilteritinib, Glofitamab, Hydroxycarbamide, Ibrutinib, Idarubicin Hydrochloride, Idelalisib, Ifosfamide, Imatinib Mesilate, Ipilimumab, Irinotecan Hydrochloride, Isatuximab, Ivosedinib, Ixazomib, Lanreotide, Lapatinib, Larotrectinib, Lenalidomide, Lenvatinib, Lomustine, Loncastuximab Tesirine, Lorlatinib, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methylprednsisolone, Midostaurin, Mitomycin, Mitotane, Mitoxantrone, Mogamulizumab, Momelotinib, Neratinib, Nilotinib, Nintedanib, Niraparib, Nivolumab, Obinutuzumab, Olaparib, Osimertinib, Oxaliplatin, Paclitaxel, Paclitaxel Albumin, Palbociclib, Panitumumab, Panobinostat, Pazopanib, Peginterferon Alfa-2A, Pembrolizumab, Pemetrexed, Pemigatinib, Pentostatin, Pertuzumab, Pixantrone, Polatuzumab- Vedotin, Pomalidomide, Ponatinib, Prednisolone, Procarbazine Hydrochloride, Raltitrexed, Retifanlimab, Regorafenib, Ribociclib, Rituximab, Ropeginterferon Alfa-2B, Rucaparib, Ruxolitinib, Sacituzumab Govitecan, Selinexor, Selpercatinib, Sorafenib, Sotorasib, Sunitinib, Talazoparib, Tebentafusp, Teclistamab, Temozolomide, Tepotinib, Thalidomide (Immunomodulating), Thiotepa, Topotecan, Trametinib, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Tretinoin, Trifluridine With Tipiracil, Tucatinib, Venetoclax, Vinblastine Sulfate, Vincristine Sulfate, Vinorelbine, Vismodegib, Zanubrutinib
Brand Names Include :
Important Information :

Refer to the St Luke's SACT protocols for oncology regimens and guidelines SACT Protocols and Policies | Royal Surrey NHS Foundation Trust

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
0